EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Development of a preclinical testing platform for clinically relevant therapy for Dravet syndrome

Jeffrey A Mensah iD, Kyle E Thomson iD, Jennifer L Huff, Tia Freeman, Christopher A Reilly iD, Joseph E Rower iD, Cameron S Metcalf iD, Karen S Wilcox iD

Epilepsia · 2025

DOI: 10.1111/epi.18516 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia, 2025. Verfasst von Jeffrey A Mensah und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Epilepsies, Myoclonic, Dioxolanes, Anticonvulsants. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDA NIH HHS, Donald R. Gehlert Fellowship, University of Utah, National Institute of Neurological Disorders and Stroke Epilepsy Therapy Screening Program, National Institutes of Health, and Department of Health and Human S….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Patients with drug‐resistant epilepsy, including Dravet syndrome, are frequently prescribed multiple antiseizure medications. Nevertheless, people with Dravet syndrome often have inadequate seizure control, and there is an ongoing unmet clinical need to identify novel therapeutics. As a proof‐of‐principle study to further validate and characterize the Scn1a A1783V/WT mouse model and identify a drug‐testing paradigm with face, construct, and predictive validity, we assessed the efficacy of subchronic administration of stiripentol add‐on to clobazam and valproic acid at clinically relevant doses using the Scn1a A1783V/WT mouse model.

Methods

Following a 14‐day treatment, we evaluated the efficacy of stiripentol add‐on to clobazam and valproic acid using hyperthermia‐induced ( n = 6) and video‐electroencephalography (EEG) monitoring of spontaneous seizure tests ( n = 13). Valproic acid was delivered via osmotic minipump, whereas stiripentol and clobazam were administered via food pellets delivered through automatic feeders. Bioanalytical assays were performed to evaluate drug concentrations in plasma and brain using liquid chromatography–tandem mass spectrometry.

Results

Stiripentol, clobazam, N ‐desmethylclobazam, and valproic acid all yielded plasma concentrations within the therapeutic plasma concentration range for humans. Stiripentol added to clobazam and valproic acid significantly elevated the seizing temperatures in the hyperthermia‐induced seizure assay (** p = 0.0018; Log‐rank test). Clobazam, valproic acid, and stiripentol co‐administration significantly reduced spontaneous seizure frequency compared to clobazam and valproic acid combined (*** p = 0.0003, Mann–Whitney test). Significance This research lays the groundwork for exploring effective add‐on compounds to clobazam and valproic acid in treating Dravet syndrome. The study further highlights the utility of the Scn1a A1783V/WT mice in discovering therapies for Dravet syndrome–associated pharmacoresistant seizures.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epilepsies, MyoclonicDioxolanesAnticonvulsantsAnimalsMiceValproic AcidNAV1.1 Voltage-Gated Sodium ChannelClobazamDisease Models, AnimalMaleFemaleDrug Evaluation, PreclinicalElectroencephalographyDrug Therapy, Combination

Stichwörter der Autor:innen

Dravet syndromeantiseizure medicationshyperthermia‐induced seizurespolytherapyspontaneous recurrent seizures

Substanzen

stiripentolDioxolanesAnticonvulsantsValproic AcidNAV1.1 Voltage-Gated Sodium ChannelClobazamScn1a protein, mouse

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah, USA.
  • Contract Site of the NINDS Epilepsy Therapy Screening Program, Salt Lake City, Utah, USA.
  • Center for Human Toxicology, Salt Lake City, Utah, USA.

ORCID-Profile: Jeffrey A Mensah, Kyle E Thomson, Christopher A Reilly, Joseph E Rower, Cameron S Metcalf, Karen S Wilcox

Förderung

  • NIDA NIH HHS
  • Donald R. Gehlert Fellowship, University of Utah
  • National Institute of Neurological Disorders and Stroke Epilepsy Therapy Screening Program, National Institutes of Health, and Department of Health and Human S…

Zitieren

APA

Mensah, J. A., Thomson, K. E., Huff, J. L., Freeman, T., Reilly, C. A., Rower, J. E., Metcalf, C. S., & Wilcox, K. S. (2025). Development of a preclinical testing platform for clinically relevant therapy for Dravet syndrome. Epilepsia. https://doi.org/10.1111/epi.18516

Vancouver

Mensah JA, Thomson KE, Huff JL, Freeman T, Reilly CA, Rower JE, et al. Development of a preclinical testing platform for clinically relevant therapy for Dravet syndrome. Epilepsia. 2025. doi:10.1111/epi.18516

BibTeX
@article{Mensah2025,
  author = {Mensah, Jeffrey A and Thomson, Kyle E and Huff, Jennifer L and Freeman, Tia and Reilly, Christopher A and Rower, Joseph E and Metcalf, Cameron S and Wilcox, Karen S},
  title = {Development of a preclinical testing platform for clinically relevant therapy for Dravet syndrome},
  journal = {Epilepsia},
  year = {2025},
  doi = {10.1111/epi.18516}
}
Kostenlos starten →